Adoption of the income statements and the balance sheets
The Annual General Meeting approved the income statements and the balance sheets for the fiscal year 2023.

The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors that no dividend should be paid for the fiscal year 2023.

The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2023.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Annual General Meeting resolved that the Board of Directors shall consist of four persons and no deputies.

The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, on re-election of Nikolaj Sörensen, Kerstin Valinder Strinnholm and Håkan Wallin as well as election of Jonas Ekblom as board members for a period until the end of the next Annual General Meeting. Kerstin Valinder Strinnholm was re-elected Chairman of the Board for the period until the end of the next Annual General Meeting.

The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate annual fee of SEK 970,000 shall be paid to the Board members, of which SEK 400,000 to the Chairman of the Board of Directors and SEK 190,000 to each of the other Board members elected by the General Meeting.

Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.

Nomination Committee
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of three members. The Nomination Committee shall comprise one representative of each of the two largest shareholders or owner groups in the Company in terms of votes as per September 30[th], 2024, besides the Chairman of the Board of Directors.

Principles for remuneration
The Annual General Meeting resolved to approve the Board of Director's proposal for principles of remuneration to senior executives in Moberg Pharma.

Remuneration report
The Annual General Meeting resolved to approve the Board of Director's remuneration report in accordance with Chapter 8, Section 53a of the Swedish Companies Act.

Implementation of LTI 2024
The Annual General Meeting also resolved to approve the Board of Director's proposal to implement a long-term incentive program, including transfer of up to 633,247 ordinary shares to the participants and other hedging arrangements in respect of incentive programs, including authorization for the Board of Directors to resolve on a directed issue and repurchase of up to 832,213 class C shares.

Authorization to issue shares
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders' pre-emptive rights, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company's share capital by issuing new shares, warrants and/or convertible debentures in the Company. The total number of shares, warrants and/or convertible debentures issued in accordance with this authorization may be equivalent to a maximum of twenty (20) per cent of the shares in the Company at the first time the Board of Directors makes a resolution by virtue of the authorization.

Minutes from the meeting and complete resolutions
The minutes from the Annual General Meeting will be made available at the Company and on the Company's website, www.mobergpharma.com.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se

About this information
The information was submitted for publication at 4.30 p.m CEST on May 14[th], 2024, through the contact persons above.

About Moberg Pharma, www.mobergpharma.com (http://www.mobergpharma.se)
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara[®]. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).